We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Jan 2019
  • Code : CMI798
  • Pages : 184
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Renal Denervation Devices Market – Easy Administration of Medications

Renal denervation devices play a major role in modern healthcare and are used in treatment of uncontrolled or persistent hypertension, where hypertensive medication is ineffective. The procedure consists of a catheter that emits radiofrequency energy across multiple electrodes.

The global renal denervation devices market size was valued at US$ 88.6 million in 2017, and is expected to exhibit a CAGR of 35.5% over the forecast period (2018 – 2026).

Figure 1. Global Renal Denervation Devices Market Value (US$ Mn), by Region, 2017

RENAL DENERVATION DEVICES MARKET

                                                                 Source: Coherent Market Insights Analysis (2019)

Increasing prevalence of hypertension is expected to propel growth of the renal denervation devices market

Increasing prevalence of cardiovascular diseases (CVDs) and hypertension is expected to drive demand for renal denervation devices worldwide. For instance, according to the World Health Organization (WHO), the prevalence of hypertension in adults aged 25 and above was around 40% in 2008 worldwide. According to the American College of Cardiology (ACC)/the American Heart Association (AHA), the clinical practice guidelines of hypertension have modified the definition of hypertension, which has increased the prevalence of hypertension to 45.6% or around 103.3 million people in U.S. in 2017.

Furthermore, according to WHO 2017, Africa accounts for the highest number of high blood pressure cases worldwide, affecting around 46% of adults, owing to increasing urbanization and unhealthy lifestyles. According to the Blood Pressure Association in the U.K., the highest number of people suffering from high blood pressure was recorded in South Asia and parts of Africa, where over 50% of those with high blood pressure lived in Asia Pacific, including 226 million people in China and 199 million in India in 2015. Therefore, increasing number of high blood pressure cases is expected to boost the market growth.

However, adoption of pharmaceutical therapy for the management of hypertension is expected to limit adoption of renal denervation devices, thereby hindering the market growth. For instance, according to American College of Cardiology (ACC)/American Heart Association (AHA), the number of people adopting pharmaceutical therapy increased by 13.9 million (from 24.0 in 2013 % to 54.4% of the treated patients) in the U.S. in 2017. Moreover, around 30 million people in China choose pharmaceutical treatment for hypertension in 2017.

Figure 2. Global Renal Denervation Device Market Share (%), by Products, 2018 and 2026

RENAL DENERVATION DEVICES MARKET

                                                               Source: Coherent Market Insights Analysis (2019)

Increasing research and development activities and regulatory approvals in Europe is expected to bolster the market growth

Europe holds dominant position in the global renal denervation device market, owing to increasing research and development activities and regulatory approvals. For instance, in February 2014, Cordis Corporation, a division of Johnson & Johnson, received CE Mark for Renlane renal denervation system. The system consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency (RF) ablation system.

Moreover, increasing number of clinical trials on renal denervation devices is also expected to boost the market growth. For instance, multi-center, international, single-blind, randomized, sham-controlled clinical trials of RADIANCE-HTN SOLO were conducted at 21 centers in the U.S. and 18 in Europe. The trials meet primary efficacy endpoint, according to an announcement by ReCor Medical in May 2018.

Key Players

Major players operating in the global renal denervation device market include, St. Jude Medical, Inc., ReCor Medical Inc., Boston Scientific Corporation, Cardiosonic Ltd, Medtronic Plc., Kona Medical, Inc., Mercator Medsystems, Inc., Terumo Corporation, Abbott Laboratories, and Theragenics Corporation.

Frequently Asked Questions

The global renal denervation devices market is estimated to surpass US$ 1.3 Billion by 2026.

Major players operating in the global renal denervation devices market include St. Jude Medical, Inc., ReCor Medical Inc., Boston Scientific Corporation, Cardiosonic Ltd, Medtronic Plc., Kona Medical, Inc., Mercator Medsystems, Inc., Terumo Corporation, Abbott Laboratories, and Theragenics Corporation.

Adoption of pharmaceutical therapy for the management of hypertension is expected to limit adoption of renal denervation devices. This is one of the major factors that is expected to hamper growth of the market over the forecast period.

Increasing prevalence of cardiovascular diseases (CVDs) and hypertensionis one of the major factors that is expected to propel growth of the market over the forecast period.

The global renal denervation devices market is estimated to exhibit a CAGR of 35.5% over the forecast period (2018-2026).

Among regions, Europe is expected to hold dominant position in the global renal denervation devices market over the forecast period.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo